Here are several reasons Pfizer needs to sharpen its pencil


Bolstering its claim that Pfizer's (PFE) offer undervalues its pipeline, AstraZeneca (AZN) releases promising data on its lung cancer drug AZD9291. In a 199-cohort Phase 1 clinical trial, it shrank tumors in 51% of patients and 64% of patients with the T790M genetic mutation, which develops in ~50% of non-small cell lung cancer cases that become resistant to EGFR inhibitors.

A Phase 2 trial is underway in patients with the T790M mutation at a daily dose of 80 mg. If all goes well, AZN will submit its regulatory filing as early as 2H 2015.

The company believes that AZD9291 could achieve peak sales of $3B.

Another promising product is MEDI4736, a cancer immunotherapy known as an anti-PDL-1, currently being tested for non-small lung cancer. The firm believes it could achieve peak sales of $6.5B.

Yet another is olaparib, a PARP inhibitor being tested for ovarian cancer. Management believes peak sales could hit $2B.

From other sites
Comments (1)
  • Willow Street Investments
    , contributor
    Comments (2113) | Send Message
     
    The PFE deal only benefits the CEO and not the shareholders. Let PFE's pencil be dull. PFE shareholders get stuck with a tax bill if PFE redomiciles in England.
    15 May 2014, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs